Skip to main content
SpringerLink
Log in

Obstructive Uropathy and Benign Prostatic Hyperplasia

  • Chapter
The Aging Kidney in Health and Disease

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Gades, N.M., Jacobson, D.J., Girman, C.J., et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int. 2005; 95(4):549–553.

    Article  PubMed  Google Scholar 

  • Skolarikos, A., Thorpe, A.C., Neal, D.E. Lower urinary tract and benign prostatic hyperplasia. Minerva Urol. Nefrol. 2004; 56:109–122.

    PubMed  CAS  Google Scholar 

  • Thorpe, A.C., Cleary, R., Coles, J., et al. Deaths and complications following prostatectomy in 1400 men in the northern region of England. Br. J. Urol. 1994; 74:559–765.

    PubMed  CAS  Google Scholar 

  • Matthiesen, T., Ritting, S., Norgaard, J.P., et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J. Urol. 1996; 156:1292–1299.

    Article  PubMed  CAS  Google Scholar 

  • Byrne, R.L., Leung, H., Neal, D.E. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br. J. Urol. 1996; 77:627–633.

    PubMed  CAS  Google Scholar 

  • Logie, J., Clifford, G.M., Farmer, R.D. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int. 2005; 95(4):557–562.

    Article  PubMed  Google Scholar 

  • De la Rosette, J.J. What we do and don’t know about benign prostatic hyperplasia. Curr. Opin. Urol. 2000; 10:1–2.

    Article  Google Scholar 

  • Barry, M.J. Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North Am. 1990; 17:495–507.

    PubMed  CAS  Google Scholar 

  • Roberts, R.O., Jacobsen, S.J., Rhodes, T., et al. Natural history of prostatism: Impaired health states in men with lower urinary tract symptoms. J. Urol. 1997; 157:1711–1717.

    Article  PubMed  CAS  Google Scholar 

  • Boyle, P., Robertson, C., Mazzetta, C., et al. The relationship between lower urinary tract symptoms and health status: The UREPIK study. BJU Int. 2003; 92:575–580.

    Article  PubMed  CAS  Google Scholar 

  • Garraway, W.M., Collins, G.N., Lee, R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338:469–471.

    Article  PubMed  CAS  Google Scholar 

  • Sarma, A.V., Wei, J.T., Jacobson, D.J., et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: The Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men’s Health study. Urology 2003; 6l:108–191.

    Google Scholar 

  • Steyn, M. Just old age? A study of prostatism in general practice. Fam. Pract. 1988; 5:193–195.

    Article  PubMed  CAS  Google Scholar 

  • Hoesl, C.E., Woll, E.M., Burkart, M., et al. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur. Urol. 2005; 47(4):511–517.

    Article  PubMed  CAS  Google Scholar 

  • Nickel, J.C., Elhilali, M., Vallancien, G., ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: Prevalence of painful ejaculation in men with clinical BPH. BJU Int. 2005; 95(4):571–574.

    Google Scholar 

  • Roberts, R.O., Bergstralh, E.J., Cunningham, J.M., et al. Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am. J. Epidemiol. 2004 (Feb 1); 159(3):269–276.

    Google Scholar 

  • Li, Z., Habuchi, T., Tsuchiya, N., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis 2004; 25(2):237–240.

    Article  PubMed  CAS  Google Scholar 

  • Berger, A.P., Kofler, K., Bektic, J., et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57:57–65.

    Article  PubMed  CAS  Google Scholar 

  • Cazares, L.H., Adam, B.L., Ward, M.D., et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin. Can. Res. 2002; 8:254l–2552.

    Google Scholar 

  • DiSanto, M.E., Stein, R., Chang, S., et al. Alteration in expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am. J. Physiol. Cell Physiol. 2003; 285:C1397–1410.

    PubMed  CAS  Google Scholar 

  • Fong, Y.K., Milani, S., Djavan, B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr. Opin. Urol. 2005; 15(1):35–38.

    Article  PubMed  Google Scholar 

  • Rhodes, T., Blue Bell, P.A., Jacobson, D., et al. Longitudinal prostate volume in a community-based sample: Long-term follow-up in the Olmsted County study of urinary symptoms and health status among men. J. Urol. 2002; l67:269.

    Google Scholar 

  • McConnell, D. The long-term effects of medical therapy on the progression of BPH: Results from the MTOPS trial. J. Urol. 2002; l67:264.

    Google Scholar 

  • Speakman, M. Tamsulosin reduces the risk of acute urinary retention. J, Urol, 2002; l67:375.

    Google Scholar 

  • Lucas, M.G., Stephenson, T.P., Nargund, V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int. 2005; 95(3):354–357.

    Article  PubMed  CAS  Google Scholar 

  • Neal, D.E. Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet 1997; 350:305–306.

    Article  PubMed  CAS  Google Scholar 

  • Rule, A.D., Lieber, M.M., Jacobsen, S.J. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J. Urol. 2006; 173:691–696.

    Article  Google Scholar 

  • McConnell, J.D., Barry, M.J., Bruskewitz, R.C., Bueschen, A.J., Denton, S.E., Holtgrewe, N.L., et al. Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guideline, Number 8. Agency for Health Care Policy and Research. Publication No. 04–0583, Rockville, MD: Public Health Service, U.S. Department of Health and Human Services, February 1994.

    Google Scholar 

  • O’Reilly, P.H., Brooman, P.J., Farah, N.B., Mason, G.C. High pressure chronic retention. Incidence, aetiology and sinister implications. Br. J. Urol. 1986; 58:644.

    Article  PubMed  CAS  Google Scholar 

  • George, N.G., O’Reilly, P.H., Barnard, R.G., Blacklock, N.J. High pressure chronic retention. BMJ 1983; 286:1780.

    PubMed  CAS  Google Scholar 

  • George, N.G., Feneley, R.C., Roberts, J.B. Identification of the poor risk patient with “prostatism” and detrusor failure. Br. J. Urol. 1986; 58:290.

    PubMed  CAS  Google Scholar 

  • Comiter, C.V., Sullivan, M.P., Schacterle, R.S., Cohen, L.H., Valla, S.V. Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. J. Urol. 1997; 158:181.

    Article  PubMed  CAS  Google Scholar 

  • Styles, R.A., Neal, D.E., Griffiths, C.J., Ramsden, P.D. Long-term monitoring of bladder pressure in chronic retention of urine: The relationship between detrusor activity and upper tract dilatation. J. Urol. 1988; 140:330.

    PubMed  CAS  Google Scholar 

  • Jones, D.A., Giplin, S.A., Holden, D., Dixon, J.S., O’Reilly, P.H., George, N.J. Relationship between bladder morphology and long-term outcome of treatment in patients with high pressure chronic retention of urine. Br. J. Urol. 1991; 67:280.

    PubMed  CAS  Google Scholar 

  • Sutaria, P.M., Staskin, D.R. Hydronephrosis and renal deterioration in the elderly due to abnormalities of the lower urinary tract and ureterovesical junction. Int. Urol. Nephrol. 2000; 32:119.

    Article  PubMed  CAS  Google Scholar 

  • Prakash, J., Saxena, R.K., Sharma, O.P., Usha , Spectrum of renal diseases in the elderly: Single center experience from a developing country. Int. Urol. Nephrol. 2001; 133:227.

    Google Scholar 

  • Olbrich, O., Woodford-Williams, E., Irvine, R.E., Webster, D. Renal function in prostatism. Lancet 1957; 1:1322.

    Article  Google Scholar 

  • Ogbonna, B.C., Madziga, A.G., AnteyIi, E.A. The impact of renal impairment on the management of patients with lower urinary tract obstruction. Trop. Doct. 1997; 27:75.

    PubMed  CAS  Google Scholar 

  • Bhargava, S., Canda, A.E., Chapple, C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr. Opin. Urol. 2004; 14(1):1–6.

    Article  PubMed  Google Scholar 

  • Mebust, W., Roizo, R., Schroeder, F., et al. Correlations between pathology clinical symptoms and the course of the disease. In Proceedings of the International Consultation on Benign Protastic Hyperplasia, A.T.K. Cockett, Y. Aso, C. Chatelain, L. Denis, K. Griffiths, S. Khoury, et al., eds. Geneva: WHO. 1991; pp. 51–62.

    Google Scholar 

  • Bosch, J.L., Hop, W.C., Kirkels, W.J., et al. The international prostate symptom score in a community sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age. Prostate volume, flow rate and residual urine volume. Br. J. Urol. 1995; 75:622–630.

    PubMed  CAS  Google Scholar 

  • Djavan, B., Wammack, R., Dobrovits, M., et al. Predictors of progression in men with mild symptoms of bladder outlet obstruction. J. Urol. 2002; 167:268.

    Article  Google Scholar 

  • Tubaro, A., Trucchi, A., Miano, L. Investigation of benign prostatic hyperplasia. Curr. Opin. Urol. 2003; 13:17–22.

    Article  PubMed  Google Scholar 

  • Braun, M.H., Sommer, F., Haupt, G., et al. Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical “Aging Male”’ symptoms? Results of the “Cologne Male Survey.” Eur. Urol. 2003; 44:588–594.

    Article  PubMed  CAS  Google Scholar 

  • Chatelain, C., Denis, L., Foo, K.T., Khoury, S., Connell, J.M.C. Benign Prostatic Hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH), June 25–28, 2000, Paris. Plymouth, UK: Health Publication Ltd. 2001.

    Google Scholar 

  • Di Silverio, F., Sciarra, A., D’Eramo, G., et al. Relationship among age, prostate specific antigen and prostate volume in men with lower urinary tract symptoms and in different age groups of men with and without benign and malignant prostatic diseases. Prostate 1998; 36:l–7.

    Article  Google Scholar 

  • Roehrborn, C.G. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int. 2004; 93(Suppl 1):21–26.

    Article  Google Scholar 

  • Laniado, M.E., Ockrim, J.L., Marronaro, A., et al. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int. 2004; 94(9):1283–1286.

    Article  PubMed  Google Scholar 

  • Wright, E.J., Fang, J., Metter, E.J., et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging. J. Urol. 2002; 167:2484–2488.

    Article  PubMed  Google Scholar 

  • Chatelain, C.H., Denis, L., Foo, K.T., et al. Evaluation and treatment of lower urinary tract symptoms in older men. Recommendations of the 5th International Consultation on Benign Prostatic Hyperplasia. June 25–28, 2000. Paris, Plymouth, UK: Health Publication Ltd. 2001; pp. 519–533.

    Google Scholar 

  • Flanigan, R.C., Reda, D.J., Wasson, J.H., et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia. A Department of Veterans Affairs cooperative study. J. Urol. 1998; l60:12–16.

    Google Scholar 

  • AUA Practice Guidelines Committee. AUA guideline of management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J. Urol. 2003; 170:530–547.

    Article  Google Scholar 

  • Souverein, P.C., van Reimsdijk, M.M., de la Rosette, J.J., et al. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: A population-based cohort study in the Netherlands. Eur. Urol. 2005; 47(4):505–510.

    Article  PubMed  CAS  Google Scholar 

  • de Nunzio, C., Franko, G., Rocchegiani, A., et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J. Urol. 2003; 169(2):535–539.

    Article  PubMed  Google Scholar 

  • Borth, C.S., Beiko, D.T., Nickel, J.C. Impact of medical therapy on transurethral resection of the prostate: A decade of change. Urology 2001; 57:1082–1085.

    Article  PubMed  CAS  Google Scholar 

  • Fong, Y.K., Milani, S., Djavan, B. Role of phytotherapy in men with lower urinary tract symptoms. Curr. Opin. Urol. 2005; 15(1):45–48.

    Article  PubMed  Google Scholar 

  • Lowe, F.C., Fagelman, E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr. Opin. Urol. 2002; 12:15–18.

    Article  PubMed  Google Scholar 

  • Debruyne, F., Koch, G., Boyle, P., et al. Comparison of a phytotherapeutic agent (permixon) with an a-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur. Urol. 2002; 4l:497–506, discussion 506–507.

    Article  Google Scholar 

  • Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E.S., Goldberg, H., Avins, A.L. Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med. 2006; 354(6):557–566.

    Article  PubMed  CAS  Google Scholar 

  • Talpur, N., Echard, B., Bagchi, D., et al. Comparison of saw palmetto (extract and whole berry) and Cemitin on prostate growth in rats. Mol. Cell Biochem. 2003; 250:21–26.

    Article  PubMed  CAS  Google Scholar 

  • Wadsworth, T.L., Carroll, J.M., Mallinson, R.A., et al. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004; 145(7):3205–3214.

    Article  PubMed  CAS  Google Scholar 

  • Lepor, H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br. J. Urol. 1998; 81:29–33.

    PubMed  Google Scholar 

  • Kyprianou, N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J. Urol. 2003; 169:1520–1525.

    Article  PubMed  CAS  Google Scholar 

  • Forray, C., Bard, J.A., Wetzel, J.M., et al. The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned alphaC subtype. Mol. Pharmacol. 1994; 45:703–708.

    PubMed  CAS  Google Scholar 

  • Chapple, C.R. α-adrenoceptor antagonists in the year 2000: Is there anything new? Curr. Opin. Urol. 2001; 11:9–16.

    Article  PubMed  CAS  Google Scholar 

  • Narayan, P., Evans, C.P., Moon, T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J. Urol. 2003; 170(2 Pt 1):498–502.

    Article  PubMed  Google Scholar 

  • Nordling, J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005; 95(7):1006–1012.

    Article  PubMed  CAS  Google Scholar 

  • Bartsch, G., Rittmaster, R.S., Klocker, H. Dihydrotestosterone and the concept of 5-α reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 2000; 37:367–380.

    Article  PubMed  CAS  Google Scholar 

  • Clark, R., Hermann, D., Gabriel, H., et al. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5-α reductase inhibitor. J. Urol. 1999; 161:1037.

    Article  Google Scholar 

  • Roehrborn, C.G., Bruskewitz, R., Nickel, G.C., et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. Eur. Urol. 2000; 37:528–536.

    Article  PubMed  CAS  Google Scholar 

  • Andriole, G.L., Kirby, R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. 2003; 44:82–88.

    Article  PubMed  CAS  Google Scholar 

  • Lam, J.S., Romas, N.A., Lowe, F.C. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003; 61:354–358.

    Article  PubMed  Google Scholar 

  • Wesselis, H., Roy, J., Bannow, J., et al. PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61:579–584.

    Article  Google Scholar 

  • Desgrandchamps, F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: A reflection from MTOPS. Curr. Opin. Urol. 2004; 14(1):17–20.

    Article  PubMed  Google Scholar 

  • Baldwin, K.G., Ginsberg, P.C., Roehrborn, C.G., et al. Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58:203–209.

    Article  PubMed  CAS  Google Scholar 

  • Reynard, J.M. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr. Opin. Urol. 2004; 14(1):13–16.

    Article  PubMed  Google Scholar 

  • Freyer, P. One thousand cases of total enucleation of the prostate for radical cure of enlargement of that organ. BMJ 1912; 2:868.

    Google Scholar 

  • Millin, T. Retropubic Urinary Surgery. London: Livingstone. 1947.

    Google Scholar 

  • Walsh, T.N., Kelly, D.G. Historical review of prostatectomy. In The Prostate, J.M. Fitzpatrick and R.J. Krane, eds. London: Churchill Livingstone. 1989; pp. l43–147.

    Google Scholar 

  • Blandy, J.P. Transurethral prostatectomy. In The Prostate, J.R. Blandy and B. Lytton, eds. London: Butterworth. 1986; pp. 51–61.

    Google Scholar 

  • Walsh, A. Indications for prostatic surgery and selection of operation. In The Prostate, J.M. Fitzpatrick and R.J. Krane, eds. London: Churchill Livingstone. 1989; pp. l37–142.

    Google Scholar 

  • Thomas, A.W., Cannon, A., Bartlett, E., et al. The natural history of lower urinary tract dysfunction in men: The influence of detrusor under-activity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004; 93(6):745–750.

    Article  PubMed  CAS  Google Scholar 

  • Roos, N.P., Wennberg, J.E., Malenka, D.J., et al. Mortality and re-operation after open and transurethral resection of the prostate. N. Engl. J. Med. 1989; 320:1120–1124.

    Article  PubMed  CAS  Google Scholar 

  • Brookes, S.T., Donovan, J.L., Peters, T.J., et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: Evidence from randomized controlled trial. BMJ 2002; 324:1059–1061.

    Article  PubMed  Google Scholar 

  • Smith, D., Khoubehi, B., Patel, A. Bipolar electrosurgery for benign prostatic hyperplasia: Transurethral electrovaporization and resection of the prostate. Curr. Opin. Urol. 2005; 15(2):95–100.

    Article  PubMed  Google Scholar 

  • Wilson, J.R., Urwin, G.H., Stower, M.J. The changing practice of transurethral prostatectomy: A comparison of cases performed in 1990 and 2000. Ann. Roy. Coll. Surg. Engl. 2004; 86(6):428–431.

    Article  CAS  Google Scholar 

  • Pickard, R., Emberton, M., Neal, D.E. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br. J. Urol. 1998; 81(5):712–720.

    PubMed  CAS  Google Scholar 

  • Ghalayini, I.F., Al-Ghazo, M.A., Pickard, R.S. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention. BJU Int. 2005; 96(1):93–97.

    Article  PubMed  Google Scholar 

  • Emberton, M., Neal, D.E., Black, N., et al. Effect of prostatectomy on symptom scoring and quality of life. Br. J. Urol. 1996; 77:233–247.

    PubMed  CAS  Google Scholar 

  • Kabelin, J.R., Gillings, P.J., Praundorfer, M.R. Hoimiumyttrium-aluminium-garnet laser prostatectomy. Mayo Clinic Proc. 1998; 73:792–797.

    Google Scholar 

  • Tan, A.H., Gilling, P.J. Lasers in the treatment of benign prostatic hyperplasia: An update. Curr. Opin. Urol. 2005; 15(1):55–58.

    Article  PubMed  Google Scholar 

  • Barber, N.J., Muir, G.H. High-power KTP laser prostatectomy: The new challenge to transurethral resection of the prostate. Curr. Opin. Urol. 2004; 14(1):21–25.

    Article  PubMed  Google Scholar 

  • Hoffman, R.M., MacDonald, R., Wilt, T.J. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst. Rev. 2004; (1):CD001987.

    Google Scholar 

  • Seki, N., Mochida, O., Kinukawa, N., et al. Holmium laser enucleation for prostatic adenoma: Analysis of learning curve over the course of 70 consecutive cases J. Urol. 2003; 170:1847–1850.

    Article  PubMed  Google Scholar 

  • Naspro, R., Salonia, A., Colombo, R., et al. Update of the minimally invasive therapies for benign prostatic hyperplasia. Curr. Opin. Urol. 2005; 15(1):49–53.

    Article  PubMed  Google Scholar 

  • Denovec, M., Houdelette, P. Columbeau, P., et al. A multicenter study of SHAM versus thermotherapy in benign prostatic hypertrophy. J. Urol. 1994; 151:415.

    Google Scholar 

  • Hoffman, R.M., MacDonald, R., Monga, M., et al. Transurethral microwave thermotherapy vs. transurethral resection for treating benign prostatic hyperplasia: A systematic review. BJU Int. 2004; 94(7):1031–1036.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Gerasimos Alivizatos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Skolarikos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departamento de Medicina, University of Salamanca, Salamanca, Spain

    Juan F. MachasNúñez M.D., Ph.D (Profesor Titular de Medicina) (Profesor Titular de Medicina)

  2. Guy’s King’s and St. Thomas’ School of Medicine King’s College, London, UK

    J. Stewart Cameron M.D., B.Sc., FRCP (Emeritus Professor of Renal Medicine) (Emeritus Professor of Renal Medicine)

  3. Toronto Western Hospital, Toronto, Ontario, Canada

    Dimitrios G. Oreopoulos M.D., Ph.D. (Professor of Medicine) (Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Alivizatos, G., Skolarikos, A. (2008). Obstructive Uropathy and Benign Prostatic Hyperplasia. In: MachasNúñez, J.F., Cameron, J.S., Oreopoulos, D.G. (eds) The Aging Kidney in Health and Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72659-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-72659-5_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-72658-8

  • Online ISBN: 978-0-387-72659-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation